DEXCOM INC — Director's Dealing 2016

Mar 10, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2016-03-08

Reporting Person: DOUBLEDAY RICHARD (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-08	Common Stock	A	38000.0	$0.0010	Acquired	138856	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15073	Indirect

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2: Included in this number are 99,667 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 31,666 of which were granted on March 8, 2015 and shall vest through March 8, 2018, 16,667 of which were granted on March 8, 2014 and shall vest through March 8, 2017, 5,000 of which were granted on May 31, 2013 and shall vest through May 31, 2016, and 8,334 of which were granted on March 11, 2013 and shall vest through March 11, 2016.

F3: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.